C J S Kronborg1, A R Jensen. 1. Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark, camkro@rm.dk.
Abstract
PURPOSE: The purpose of this study is to identify treatment-related factors prognostic of survival in a cohort of patients with metastatic colorectal cancer (mCRC) receiving a palliative, stop-and-go chemotherapy regimen. METHODS: Consecutive patients receiving first-line treatment with biweekly FLIRI plus bevacizumab were included. The outcome was overall survival. Cox regression analysis was used to identify predictors of outcome. We analysed reduction in chemotherapy dosage (no vs. ≤25 or >25 % reduction), bevacizumab administrated to <50, or ≥50 % to chemotherapy treatments, best response during the first 24 weeks of treatment, and local treatment of metastases. RESULTS: We included 257 patients. Median survival was 23.6 months. Chemotherapy reduction did not influence outcome. Bevacizumab administrations (≥50 %) were associated with improved outcome: hazard ratios (HR) 0.56 (95 % confidence interval (CI) 0.34-0.90, p = 0.018). Partial response (PR) vs. no change (NC) was borderline significant: HR 0.66 (95 % CI 0.43-0.99, p = 0.048), whereas progressive disease (PD) vs. NC increased mortality HR 2.48 (95 % CI 1.19-5.19, p = 0.016). Local treatment of metastases improved outcome: HR 0.30 (95 % CI 0.15-0.61, p = 0.001). CONCLUSIONS: In a cohort of mCRC patients, receiving a palliative, stop-and-go regimen, administration of bevacizumab to ≥50 % of chemotherapy treatments and local treatment of metastases were associated with better survival. PR improved outcome compared to NC, whereas PD was prognostic of increased mortality.
PURPOSE: The purpose of this study is to identify treatment-related factors prognostic of survival in a cohort of patients with metastatic colorectal cancer (mCRC) receiving a palliative, stop-and-go chemotherapy regimen. METHODS: Consecutive patients receiving first-line treatment with biweekly FLIRI plus bevacizumab were included. The outcome was overall survival. Cox regression analysis was used to identify predictors of outcome. We analysed reduction in chemotherapy dosage (no vs. ≤25 or >25 % reduction), bevacizumab administrated to <50, or ≥50 % to chemotherapy treatments, best response during the first 24 weeks of treatment, and local treatment of metastases. RESULTS: We included 257 patients. Median survival was 23.6 months. Chemotherapy reduction did not influence outcome. Bevacizumab administrations (≥50 %) were associated with improved outcome: hazard ratios (HR) 0.56 (95 % confidence interval (CI) 0.34-0.90, p = 0.018). Partial response (PR) vs. no change (NC) was borderline significant: HR 0.66 (95 % CI 0.43-0.99, p = 0.048), whereas progressive disease (PD) vs. NC increased mortality HR 2.48 (95 % CI 1.19-5.19, p = 0.016). Local treatment of metastases improved outcome: HR 0.30 (95 % CI 0.15-0.61, p = 0.001). CONCLUSIONS: In a cohort of mCRC patients, receiving a palliative, stop-and-go regimen, administration of bevacizumab to ≥50 % of chemotherapy treatments and local treatment of metastases were associated with better survival. PR improved outcome compared to NC, whereas PD was prognostic of increased mortality.
Authors: R Labianca; A Sobrero; L Isa; E Cortesi; S Barni; D Nicolella; M Aglietta; S Lonardi; D Corsi; D Turci; G D Beretta; G Fornarini; E Dapretto; I Floriani; A Zaniboni Journal: Ann Oncol Date: 2010-11-15 Impact factor: 32.976
Authors: Kjell Magne Tveit; Tormod Guren; Bengt Glimelius; Per Pfeiffer; Halfdan Sorbye; Seppo Pyrhonen; Fridbjorn Sigurdsson; Elin Kure; Tone Ikdahl; Eva Skovlund; Tone Fokstuen; Flemming Hansen; Eva Hofsli; Elke Birkemeyer; Anders Johnsson; Hans Starkhammar; Mette Karen Yilmaz; Nina Keldsen; Anne Berit Erdal; Olav Dajani; Olav Dahl; Thoralf Christoffersen Journal: J Clin Oncol Date: 2012-04-02 Impact factor: 44.544
Authors: Michalis Zacharakis; Ioannis D Xynos; Andreas Lazaris; Tsaousi Smaro; Christos Kosmas; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aris Polyzos; John Sarantonis; John Syrios; George Zografos; Alexandros Papalambros; Nikolas Tsavaris Journal: Anticancer Res Date: 2010-02 Impact factor: 2.480
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Clemens Giessen; Ruediger P Laubender; Ludwig Fischer von Weikersthal; Andreas Schalhorn; Dominik P Modest; Sebastian Stintzing; Michael Haas; Ulrich R Mansmann; Volker Heinemann Journal: Cancer Sci Date: 2013-04-15 Impact factor: 6.716
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: James Cassidy; Leonard B Saltz; Bruce J Giantonio; Fairooz F Kabbinavar; Herbert I Hurwitz; Ulrich-Peter Rohr Journal: J Cancer Res Clin Oncol Date: 2009-11-11 Impact factor: 4.553